Lingkai Weng

USPTO Granted Patents = 15 (Patent Applications = 3)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 5.6

ph-index = 6

Forward Citations = 94(Granted Patents)

Location History:

Malvern, PA (US) (2013 - 2022)
Phoenixville, PA (US) (2019 - 2024)

Company Filing History:

Incyte Holdings Corporation

Inctye Holdings Corporation

patent

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12427154 - Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2025-09-30),

2. 12024522 - Salts and processes of preparing a PI3K inhibitor (2024-07-02),

3. 11452726 - Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2022-09-27),

4. 11207302 - 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase (2021-12-28),

5. 11084822 - Salts and processes of preparing a PI3K inhibitor (2021-08-10),

6. 10799509 - Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2020-10-13),

7. 10336759 - Salts and processes of preparing a PI3K inhibitor (2019-07-02),

8. 10280157 - Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor (2019-05-07),

9. 10245265 - Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2019-04-02),

10. 9873688 - Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor (2018-01-23),

11. 9732097 - Process for the synthesis of a phosphoinositide 3-kinase inhibitor (2017-08-15),

12. 9321755 - Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor (2016-04-26),

13. 8901123 - Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2014-12-02),

14. 8796319 - 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase (2014-08-05),

15. 8420645 - Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same (2013-04-16),

Title: Lingkai Weng: Innovator in Pharmaceutical Chemistry

Introduction

Lingkai Weng is a prominent inventor based in Malvern, PA, known for his significant contributions to pharmaceutical chemistry. With a total of 15 patents to his name, Weng has made remarkable advancements in the field, particularly in the development of kinase inhibitors.

Latest Patents

Weng's latest patents include innovative compounds such as salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide. This invention focuses on dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor, which are essential for treating cancer and other diseases linked to dysregulated kinase pathways. Additionally, he has developed processes for preparing a PI3K inhibitor, specifically (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is crucial for inhibiting phosphoinositide 3-kinase-delta (PI3Kδ).

Career Highlights

Throughout his career, Weng has worked with notable companies such as Incyte Corporation and Incyte Holdings Corporation. His work has significantly impacted the pharmaceutical industry, particularly in drug development and innovation.

Collaborations

Weng has collaborated with talented individuals in his field, including Jiacheng Zhou and Lei Qiao. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion

Lingkai Weng's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment and kinase pathway regulation.

This text is generated by artificial intelligence and may not be accurate.